Patents by Inventor CHAD GROER

CHAD GROER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Platinum(IV) conjugates and methods of use
    Patent number: 11458163
    Abstract: Provided are platinum(IV) compounds of Formula I or pharmaceutically acceptable salts thereof. Also provided are compositions including such compounds as well as methods of using the same.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: October 4, 2022
    Assignees: University of Kansas, HylaPharm, LLC
    Inventors: Laird Forrest, Daniel Aires, Ryan Moulder, Ruolin Lu, Jordan Hunt, Peter Kleindl, Ti Zhang, Chad Groer, Shuang Cai
  • IMIDAZOQUINOLINE COMPOUNDS AND PRODRUGS THEREOF
    Publication number: 20220177472
    Abstract: The present technology is directed to TLR7 and TLR8 agonist compounds, compositions, and methods of using the same for the treatment of cancers and as vaccine adjuvants.
    Type: Application
    Filed: April 16, 2020
    Publication date: June 9, 2022
    Applicants: UNIVERSITY OF KANSAS, HYLAPHARM, LLC.
    Inventors: Laird Forrest, Daniel Aires, Ryan Moulder, Ruolin Lu, Jordan Hunt, Peter Kleindl, Ti Zhang, Chad Groer, Shuang Cai
  • PLATINUM(IV) CONJUGATES AND METHODS OF USE
    Publication number: 20200330507
    Abstract: Provided are platinum(IV) compounds of Formula I or pharmaceutically acceptable salts thereof. Also provided are compositions including such compounds as well as methods of using the same.
    Type: Application
    Filed: April 16, 2020
    Publication date: October 22, 2020
    Applicants: University of Kansas, HylaPharm, LLC
    Inventors: Laird Forrest, Daniel Aires, Ryan Moulder, Ruolin Lu, Jordan Hunt, Peter Kleindl, Ti Zhang, Chad Groer, Shuang Cai
  • DRUG DELIVERY COMPOSITIONS AND METHODS
    Publication number: 20190015518
    Abstract: One aspect of the present invention is directed to conjugates that comprise a linear polymer carrier, a linker and one or more drugs or imaging agents, as well as pharmaceutical compositions that include such conjugates. The drug may be a platinum-containing drug with a linker comprised of a modified amino acid. The conjugate may alternatively include a metal complexing ligand with a metal used for imaging or chemotherapeutic purposes. Another aspect of the invention is directed to formulations and processes for lyophilization of hyaluronan conjugates. Another aspect of the invention is directed to methods for treating and/or inhibiting cancer utilizing the conjugates and compositions described herein.
    Type: Application
    Filed: January 4, 2017
    Publication date: January 17, 2019
    Inventors: MARCUS LAIRD FORREST, SHUANG CAI, TI ZHANG, SP SANJEEWA NILENDRA SENADHEERA, CHAD GROER, DANIEL AIRES
  • TARGETED MTOR INHIBITORS
    Publication number: 20160279108
    Abstract: The present invention is directed to drug conjugates of mTOR inhibitors comprising an mTOR inhibitor, such as rapamycin, conjugated to hyaluronic acid by a linker comprising an ester, carbonate, or carbamate. The present invention is also directed to pharmaceutical compositions comprising the drug conjugates, and methods of making and using the drug conjugates and the pharmaceutical compositions.
    Type: Application
    Filed: February 24, 2016
    Publication date: September 29, 2016
    Applicants: UNIVERSITY OF KANSAS, NANOPHARM LLC (d/b/a HYLAPHARM)
    Inventors: MARCUS LAIRD FORREST, TI ZHANG, S P SANJEEWA N. SENADHEERA, DANIEL AIRES, YUNQI ZHAO, SHAOFENG DUAN, CHAD GROER